2021 年 47 巻 5 号 p. 250-255
It is essential to understand the risk factors for developing proteinuria because the development of ramucirumab-induced proteinuria can interrupt the treatment. Although several previous studies of ramucirumab-induced proteinuria have been reported, there is little evidence on time-dependent risk factors for developing proteinuria. The study subjects were 86 patients with cancer treated with ramucirumab at Ako City Hospital or Okayama University Hospital. We retrospectively evaluated the predictive factors for the development of ramucirumab-induced proteinuria ≥ 2+, which is a more important criterion for interrupting ramucirumab treatment in clinical practice. Sixty-five (75.6％) and 21 (24.4％) patients developed proteinuria ≤ 1+ and ≥ 2+. The incidence of proteinuria ≥ 2+ was significantly higher in patients who were previously treated with bevacizumab than those who were not (41.4％ vs 15.8％, P = 0.016). Multivariate Cox proportional hazards model revealed that previous bevacizumab treatment was significantly associated with the development of proteinuria ≥ 2+ (hazard ratio, 2.74; 95％ confidence interval, 1.06 - 7.19; P = 0.038). These results suggest that patients who have previously been treated with bevacizumab should be monitored carefully for the development of proteinuria after ramucirumab treatment.
